NMD Pharma
NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen - Ownr.dk
NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma
NMD Pharma Information | NMD Pharma Profile
NMD Pharma A/S | LinkedIn
HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma A/S | LinkedIn
NMD Pharma - PIR International
Management team — NMD Pharma
PRESS RELEASE NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth
Management team — NMD Pharma
NMD Pharma Information | NMD Pharma Profile
NMD Pharma - PIR International
NMD Pharma - Inkef capital
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
Management team — NMD Pharma
Your career — NMD Pharma
NMD Pharma A/S | LinkedIn
Management team — NMD Pharma
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized pl
Patient Dosing Begins in Early Trial of Oral NMD670 for Myasthenia Gravis
Katja Krustrup Pedersen - Research Scientist and Project Manager - NMD Pharma | LinkedIn
